Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0HS5V
|
||||
Former ID |
DNCL002613
|
||||
Drug Name |
Brivanib
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Breast cancer; Liver cancer [ICD9: 174, 175, 140-229, 155, 203.0; ICD10:C50, C22] | Phase 3 | [1], [2] | ||
Company |
Bristol-Myers Squibb
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C19H19FN4O3
|
||||
InChI |
InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
|
||||
InChIKey |
WCWUXEGQKLTGDX-LLVKDONJSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
16317953, 23414456, 42313638, 77365611, 92721417, 99436978, 103483726, 104069124, 124490329, 124756986, 125163791, 126619161, 126661321, 126661731, 126730839, 131480673, 134343564, 134964399, 135252957, 135727386, 136367284, 136368025, 136377882, 136920387, 137276004, 141643704, 144115752, 152059805, 152088878, 152258181, 152344141, 160647017, 162011436, 162029696, 162110616, 162200058, 164041879, 164775472, 170500439, 174475086, 174539891, 177748734, 178102299, 180404088, 184816398, 188899522, 198948130, 223573483, 223677759, 223705289
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Modulator | [3] | |
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancer | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY network | |||||
Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
VEGF binds to VEGFR leading to receptor dimerization | |||||
Integrin cell surface interactions | |||||
EPHA-mediated growth cone collapse | |||||
VEGFA-VEGFR2 Pathway | |||||
VEGFR2 mediated cell proliferation | |||||
WikiPathways | Focal Adhesion | ||||
Nifedipine Activity | |||||
Cardiac Progenitor Differentiation | |||||
Signaling by VEGF | |||||
Angiogenesis | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT01108705) Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment. U.S. National Institutes of Health. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5671). | ||||
REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.